Nurix Therapeutics Competitors

Sana Biotechnology (NASDAQ:SANA) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Insider & Institutional Ownership

82.0% of Nurix Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Sana Biotechnology and Nurix Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Sana Biotechnology and Nurix Therapeutics' gross revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current recommendations for Sana Biotechnology and Nurix Therapeutics, as reported by MarketBeat.com.

Sana Biotechnology currently has a consensus target price of $40.00, suggesting a potential upside of 59.74%. Nurix Therapeutics has a consensus target price of $46.80, suggesting a potential upside of 56.05%. Given Sana Biotechnology's higher possible upside, research analysts clearly believe Sana Biotechnology is more favorable than Nurix Therapeutics.

Summary

Nurix Therapeutics beats Sana Biotechnology on 3 of the 4 factors compared between the two stocks.

Abcam (NASDAQ:ABCM) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Insider & Institutional Ownership

82.0% of Nurix Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Abcam and Nurix Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Abcam and Nurix Therapeutics' gross revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current recommendations for Abcam and Nurix Therapeutics, as reported by MarketBeat.com.

Abcam currently has a consensus target price of $22.00, suggesting a potential upside of 12.47%. Nurix Therapeutics has a consensus target price of $46.80, suggesting a potential upside of 56.05%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Abcam.

Summary

Nurix Therapeutics beats Abcam on 4 of the 4 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Profitability

This table compares Seer and Nurix Therapeutics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

82.0% of Nurix Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Seer and Nurix Therapeutics' gross revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current recommendations for Seer and Nurix Therapeutics, as reported by MarketBeat.com.

Seer currently has a consensus target price of $68.00, suggesting a potential upside of 26.25%. Nurix Therapeutics has a consensus target price of $46.80, suggesting a potential upside of 56.05%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Seer.

Summary

Nurix Therapeutics beats Seer on 4 of the 4 factors compared between the two stocks.

Nuvation Bio (NYSE:NUVB) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Profitability

This table compares Nuvation Bio and Nurix Therapeutics' net margins, return on equity and return on assets.

Insider and Institutional Ownership

82.0% of Nurix Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Nuvation Bio and Nurix Therapeutics' gross revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of current ratings for Nuvation Bio and Nurix Therapeutics, as reported by MarketBeat.com.

Nuvation Bio presently has a consensus target price of $17.40, suggesting a potential upside of 74.52%. Nurix Therapeutics has a consensus target price of $46.80, suggesting a potential upside of 56.05%. Given Nuvation Bio's higher possible upside, analysts clearly believe Nuvation Bio is more favorable than Nurix Therapeutics.

ImmunityBio (NASDAQ:IBRX) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a summary of current ratings for ImmunityBio and Nurix Therapeutics, as reported by MarketBeat.com.

ImmunityBio presently has a consensus target price of $25.00, suggesting a potential upside of 38.35%. Nurix Therapeutics has a consensus target price of $46.80, suggesting a potential upside of 56.05%. Given Nurix Therapeutics' higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than ImmunityBio.

Profitability

This table compares ImmunityBio and Nurix Therapeutics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares ImmunityBio and Nurix Therapeutics' gross revenue, earnings per share and valuation.

Insider and Institutional Ownership

82.0% of Nurix Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Nurix Therapeutics beats ImmunityBio on 3 of the 3 factors compared between the two stocks.

Nurix Therapeutics (NASDAQ:NRIX) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Insider & Institutional Ownership

82.0% of Nurix Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Nurix Therapeutics and Immunocore, as reported by MarketBeat.

Nurix Therapeutics presently has a consensus target price of $46.80, indicating a potential upside of 56.05%. Immunocore has a consensus target price of $54.3333, indicating a potential upside of 37.55%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Nurix Therapeutics is more favorable than Immunocore.

Earnings & Valuation

This table compares Nurix Therapeutics and Immunocore's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Nurix Therapeutics and Immunocore's net margins, return on equity and return on assets.

Summary

Nurix Therapeutics beats Immunocore on 4 of the 4 factors compared between the two stocks.